These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Seystahl K; Weller M Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Chinot OL Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106 [TBL] [Abstract][Full Text] [Related]
4. The role of avastin in the management of recurrent glioblastoma. Sweet JA; Feinberg ML; Sherman JH Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876 [TBL] [Abstract][Full Text] [Related]
5. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Lucio-Eterovic AK; Piao Y; de Groot JF Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589 [TBL] [Abstract][Full Text] [Related]
6. [Angiogenesis and anti-angiogenic strategies for glioblastoma]. de Boüard S; Guillamo JS Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors in the treatment of lung cancer. Sun S; Schiller JH Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for the treatment of glioblastoma. Chowdhary S; Chamberlain M Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194 [TBL] [Abstract][Full Text] [Related]
9. VEGF Manipulation in Glioblastoma. Weathers SP; de Groot J Oncology (Williston Park); 2015 Oct; 29(10):720-7. PubMed ID: 26470893 [TBL] [Abstract][Full Text] [Related]
11. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme. Spasic M; Chow F; Tu C; Nagasawa DT; Yang I Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654 [TBL] [Abstract][Full Text] [Related]
12. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Narita Y Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688 [TBL] [Abstract][Full Text] [Related]
13. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies. Boer JC; Walenkamp AM; den Dunnen WF Crit Rev Oncol Hematol; 2014 Oct; 92(1):38-48. PubMed ID: 24933160 [TBL] [Abstract][Full Text] [Related]
14. Angiogenic inhibition in high-grade gliomas: past, present and future. Jo J; Schiff D; Purow B Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175 [TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Miletic H; Niclou SP; Johansson M; Bjerkvig R Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067 [TBL] [Abstract][Full Text] [Related]